info@seagull-health.com

SeagullHealth

语言:

Homepage

Drugs

Capmatinib(Tabrecta)

Names

卡马替尼,妥瑞达

Indicatons

Treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations.

Price:

Manufacturer:

Novartis

Dosage form:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Tabrecta(Capmatinib) Instructions:Uses,Dosage, Side Effects

TABRECTA, with the generic name Capmatinib, is a targeted kinase inhibitor therapy. Its active pharmaceutical ingredient is capmatinib, formulated as film-coated tablets available in 150 mg and 200 mg strengths. The drug is specifically designed to target and inhibit the MET kinase, including the mutant variant caused by MET exon 14 skipping. This mutation leads to dysregulated MET signaling and drives cancer growth. TABRECTA is manufactured and distributed by Novartis Pharmaceuticals Corporation for oral administration in eligible adult patients.

Generic name

Capmatinib(Tabrecta)

English name

Capmatinib

Alternative Names

卡马替尼,妥瑞达

Drug prices

Indications

TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.

Therapeutic Target

MET

Active Ingredients

Capmatinib

Dosage Form

TABLET

Specifications

200mg * 56 tablets/box

Dosage and Administration

The recommended dosage is 400 mg taken orally twice daily, with or without food.

Related Columns

Recommended articles

Contraindications and Adverse Reactions of Capmatinib

Capmatinib is used for metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping. It has no absolute contraindications, but several adverse reactions require close monit...

Dietary precautions for patients with Capmatinib

Capmatinib may be taken with or without food, but dietary components, dosing habits, and concomitant medications can directly affect efficacy and safety. The following explains administration, dietary...

Usage and dosage of Capmatinib

Capmatinib is a MET kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer harboring a mutation that leads to MET exon 14 skipping. The following exp...

Guidelines for Adverse Effect Management and Storage of Capmatinib (Tabrecta)

While effectively inhibiting tumors, capmatinib (Tabrecta) may induce a variety of adverse reactions.I. Common Adverse Effects of Capmatinib1. Adverse effects with an incidence rate ≥ 20%The most freq...

Capmatinib (Tabrecta): Dosage, Precautions and Healthy Lifestyle Guidelines

Standardized medication is the cornerstone for the efficacy of capmatinib. Combined with scientific health management, it can reduce adverse reactions and improve quality of life.I. Dosage and Adminis...

Adverse Reactions of Capmatinib (Tabrecta)

Capmatinib (Tabrecta) is a highly selective MET kinase inhibitor that has become an important targeted therapy for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 ...

Departments